Operating income before deduction of amortization: COMPASS Pathways PLC (CMPS)

Brandmark of COMPASS Pathways (CMPS)

COMPASS Pathways plc (CMPS) maintains its leadership through patents for synthetic psilocybin and its influence within US psychiatry. The EBITDA financial metric on the GURU.Markets chart confirms this stage, where 0.00 shows the value of this parameter. However, geopolitical tensions are hindering global therapy trials, although its status as the primary innovator in psychedelics ensures deep trust in the brand from the medical community.

COMPASS Pathways plc (CMPS) Operating profit EBITDA: for the period 11/23/2025 - 11/10/2026

Summary analytical data breakdowns for COMPASS Pathways (CMPS)

- share price and consensus valuation forecast:
Quote Chart COMPASS Corp|CMPS - Price Target Chart
- company stock exchange capitalization indicators:
Market Capitalization COMPASS Pathways|CMPS - Real Price to Acquire Entire Company
- balance sheet equity data:
Net Asset Value per Share COMPASS Pathways|CMPS - Book Capitalization|Market Cap to Net Assets Ratio compasspathways.com|CMPS - Company Total Assets
- company total debt and liquidity indicators:
All Debt to Shareholders' Equity Ratio COMPASS Pathways plc|CMPS - Long-Term Debt to Equity|Current Liabilities to Capital COMPASS Pathways PLC|CMPS - Company Aggregate Debts|Debt to Book Value COMPASS Pathways|CMPS - Company Long-Term Debt|Short-Term Debt COMPASS Pathways|Quick Liquidity Indicator compasspathways.com
- earnings and market multiples details:
CMPS - Company Net Income|Forward Earnings COMPASS Pathways plc|CMPS - P/E Multiple|Forward P/E Multiple compasspathways.com|CMPS - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio COMPASS Pathways|CMPS - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters COMPASS Pathways|CMPS - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months compasspathways.com|CMPS - Earnings per share growth in current year|Net earnings per share change forecast for next year COMPASS Pathways plc
Summary company analytics:CMPS - COMPASS Corp
Brand item of COMPASS Pathways plc

Anticipation of Phase 3 clinical trial results is driving the EBITDA trajectory for COMPASS Pathways plc (CMPS), reflecting the company's current lack of commercial sales. This indicator measures net cash flow from core operations before depreciation and interest, enabling an assessment of real operational efficiency and the capital burn rate, which is critical for high-risk biotech assets in the development stage.

Competitors of COMPASS Pathways plc (CMPS)

ALKS (Alkermes Corp) - Profit before deduction of interest, taxes, depreciation and amortization|AVDL - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization atai.life ATAI|GHRS (GH Research) - Operating profit before deduction of amortization|Profit before interest, taxes and amortization Mind Medicine (MindMed) Inc. (MNMD)|LBRX (LB Pharma) - Operating profit EBITDA|Operating profit before deduction of amortization Bright Minds Corp (DRUG)|Operating profit EBITDA VNDA|CYBN (cybin.com) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Alto Neuroscience ANRO|NRx Pharmaceuticals Inc. (NRXP) - Profit before interest, taxes and amortization|Cingulate Corp - Operating profit EBITDA|Silo Pharma Inc. (SILO) - Operating profit before deduction of amortization|chinapharmaholdings.com (CPHI) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization clearmindmedicine.com (CMND)|Profit before payment of interest, taxes and amortization Psyence Biomedical|Operating profit before deduction of amortization SciSparc Ltd. (SPRC)|Profit before payment of interest, taxes and amortization Seelos Therapeutics, Inc (SEEL)|VRPX: Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA KRTX (Karuna Therapeutics)